TICKERNERD
Menu
TGTXTGTXHealthcare · Biotechnology

TGTX Stock Forecast: TG Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 6 Oct 2026
$52
−3.19% on the day

The 8 Wall Street analysts covering TG Therapeutics, Inc. hold a median 12-month price target of $75 — +43.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 5 Oct 2026 — in the upper half.

Market cap
$8.3B
Ticker Nerd rank
68 / 100
Median analyst target
$75
Analysts covering
8
Revenue$240.3M+70.3% y/y
Operating income$21.7M
Net income$7.8M
Free cash flow$39.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−7.1%
1M
−6.8%
YTD
+75.1%
1Y
+42.0%
From 52W high
−11.6%
From 52W low
+93.7%
$27
$59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TGTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores TG Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 5 Oct 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
92
Momentum
87
Growth
82
Volatility
77
Revisions
46
Issuance
35
Size
17
Accruals
11

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Accruals (11): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TGTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TGTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80Jan 26Apr 26Jul 26Oct 26TGTXHigh $86Median $75Low $21

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy0 Hold1 Sell
Low $21Median $75High $86

The green dot is the last close — the median target sits +43.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 4 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
1 Sept 2026HC Wainwright & Co.ReiteratesBuy$78
7 Aug 2026JP MorganMaintainsOverweight—
7 Aug 2026JP MorganMaintainsOverweight$65 → $72
27 July 2026B. Riley SecuritiesMaintainsBuy$55 → $86
27 July 2026B. Riley SecuritiesMaintainsBuy—
13 July 2026HC Wainwright & Co.MaintainsBuy$70 → $77
13 July 2026HC Wainwright & Co.MaintainsBuy—
7 July 2026B of A SecuritiesMaintainsUnderperform$17 → $20
7 July 2026B of A SecuritiesMaintainsUnderperform—
6 July 2026HC Wainwright & Co.ReiteratesBuy$70
6 July 2026HC Wainwright & Co.ReiteratesBuy—
27 May 2026HC Wainwright & Co.ReiteratesBuy—
6 May 2026HC Wainwright & Co.MaintainsBuy—
2 Feb 2026JP MorganMaintainsOverweight—
15 Jan 2026Goldman SachsMaintainsNeutral—
3 Nov 2025JP MorganMaintainsOverweight—
6 Oct 2025HC Wainwright & Co.AssumesBuy$60
17 Sept 2025B. Riley SecuritiesMaintainsBuy—
4 Mar 2025HC Wainwright & Co.ReiteratesBuy—
15 Jan 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TGTX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

TGTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 6 Oct 2026, TG Therapeutics, Inc. returned +42.0% against +16.6% for the S&P 500, dividends included.

TGTX vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Jan 26Apr 26Jul 26Oct 26TGTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TGTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−38.1%
Analysts raising
0
Analysts cutting
3
Fundamentals

TG Therapeutics, Inc. (TGTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.7×

Cheaper than 38% of US stocks

Price / sales
10.4×

Cheaper than 14% of US stocks

Price / book
13.2×

Cheaper than 7% of US stocks

EV / EBITDA
57.9×

Cheaper than 4% of US stocks

Growth & margins
Revenue growth (YoY)
70.3%

Higher than 90% of US stocks

Earnings growth (YoY)
−72.4%

Higher than 6% of US stocks

Gross margin
82.9%

Higher than 93% of US stocks

Operating margin
9.0%

Higher than 62% of US stocks

Net margin
55.2%

Higher than 97% of US stocks

Returns & dividend
Return on equity
100.3%

Higher than 96% of US stocks

Return on assets
7.3%

Higher than 86% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

TG Therapeutics, Inc. (TGTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • TG Therapeutics, Inc. has a market value of $8.3B and an enterprise value of $7.9B.

  • Revenue in the twelve months to 30 June 2026: $799.5M. The latest quarter grew 70.3% year on year.

  • Net income over the same four quarters: $441.5M, a 55.2% net margin.

  • Diluted earnings per share, trailing twelve months: $2.74.

  • Free cash flow in the twelve months to 30 June 2026: $17.4M.

  • TG Therapeutics, Inc. spent $178.2M on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 153.1M.

  • Trailing P/E: 19.7×; forward P/E: 20.0× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • TG Therapeutics, Inc. employs 399 people — $2.0M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 6 Oct 2026

Data provided by Twelve Data

Peers

TGTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TGTXTG Therapeutics, Inc.$8.3B
68
CAICaris Life Sciences, Inc.$8.6B
35
CYTKCytokinetics, Inc.$8.7B
49
ARWRArrowhead Pharmaceuticals, Inc.$8.7B
55
PTGXProtagonist Therapeutics, Inc.$9.0B
97
AXSMAxsome Therapeutics, Inc.$9.1B
70
KYMRKymera Therapeutics, Inc.$9.1B
72

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own TG Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TGTX news & analysis

TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share

MarketBeat · 18 Sept 2026positive

TG Therapeutics CEO Mike Weiss stated that the multiple sclerosis therapy BRIUMVI has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market. The company is reportedly eyeing a $1 billion run rate.

Why it matters — A TGTX watcher would care because BRIUMVI's continued market-share gains in the MS treatment space indicate growing commercial momentum for the company's key product.

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 10 Sept 2026neutral

TG Therapeutics announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. A fireside chat is scheduled for Monday, September 14, 2026, at 12:00pm ET.

Why it matters — A TGTX watcher would care because the presentation provides management an opportunity to update investors on the company at a major investment conference.

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

GlobeNewsWire · 3 Sept 2026neutral

TG Therapeutics announced it will participate in the Cantor Global Healthcare Conference. The company said it would present at the event, according to the announcement.

Why it matters — Investors tracking TGTX may be interested in its participation in a major healthcare conference as a chance for company exposure and visibility.

TG Therapeutics (TGTX) Up 15.1% Since Last Earnings Report: Can It Continue?

Zacks Investment Research · 2 Sept 2026positive

TG Therapeutics reported earnings approximately 30 days ago, and its stock has risen 15.1% since then. The report examines whether the stock can continue its upward momentum following the earnings announcement.

Why it matters — TGTX watchers would care because the report assesses the stock's recent post-earnings performance and its potential for continued gains.

TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)

Seeking Alpha · 26 Aug 2026positive

TG Therapeutics outlined upcoming catalysts for Q4 2026 and H1 2027, including preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 and topline Phase 3 data for Briumvi SC by year-end 2026 or early 2027. The company also raised its Briumvi U.S. net product revenue guidance from $885-$900 million to $890-$905 million.

Why it matters — TGTX watchers would care because the company has disclosed a timeline of major clinical data readouts and raised its Briumvi revenue outlook, signalling the potential for meaningful developments ahead.

FAQ

Frequently asked questions about TGTX stock

What is the TGTX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering TG Therapeutics, Inc. have a median 12-month price target of $75, with estimates ranging from $21 to $86. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TGTX stock a buy right now?

Of the 8 analysts covering TG Therapeutics, Inc., 7 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks TG Therapeutics, Inc. 68 out of 100 across roughly 4,600 US stocks as at 5 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TGTX?

As at 5 Oct 2026, TG Therapeutics, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will TGTX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +43.7% from the last close, and Ticker Nerd's factor model ranks TG Therapeutics, Inc. 68 out of 100 as at 5 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TGTX stock forecast for 2030?

No analyst covering TG Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TGTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $21 to $86 over the next 12 months.

How has TGTX stock performed over the past year?

TG Therapeutics, Inc. returned +42.0% over the 12 months to 6 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does TG Therapeutics, Inc. do?

TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases.

What is the latest news on TGTX?

The most recent item we track (MarketBeat, 18 Sept 2026): "TG Therapeutics Eyes $1B Run Rate as BRIUMVI Gains MS Market Share". TG Therapeutics CEO Mike Weiss stated that the multiple sclerosis therapy BRIUMVI has captured more than one-third of the intravenous anti-CD20 market and continues to gain share as it approaches its fourth full year on the market. The company is reportedly eyeing a $1 billion run rate.

Company

About TG Therapeutics, Inc.

TG Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell mediated diseases. The company’s lead product, BRIUMVI, is an anti-CD20 monoclonal antibody used for adults with relapsing forms of multiple sclerosis, including relapsing-remitting disease, clinically isolated syndrome, and active secondary progressive disease. TG Therapeutics also advances a broader pipeline of therapies, including subcutaneous and intravenous formulations of ublituximab, along with investigational programs such as Azer-cel. Its portfolio is centered on immune-related and hematologic conditions, reflecting a business model built around specialty medicines that target B-cell activity. TG Therapeutics serves patients and healthcare providers in the United States and internationally through its marketed products and development-stage candidates.

CEO Mr. Michael S. Weiss Esq., J.D. · 399 employees · United States · https://www.tgtherapeutics.com